oasis-1 oral semaglutide 50 mg obesity nejm 2023 Once-Weekly in Adults with Overweight or FDA approves once-daily oral Wegovy®

Eligibility, subject to clinical assessment Wegovy may be supplied to adults who: have a BMI of 30 kg/m or above , or have a BMI of 27 kg/m or above with at least one weight-related health condition , for example high blood pressure, hypertension, high cholesterol, dyslipidaemia, obstructive sleep apnoea or type 2 diabetes

Over the course of the study, 26% of GLP-1 users stopped taking the medication and about 23% had an interruption of six months or more followed by resuming treatment

Semaglutide should be used in conjunction with other weight loss measures, including increased physical activity and reduced caloric intake

Kidney Impairment: While not a total contraindication, dehydration from GI side effects can stress the kidneys

this interaction is enhanced by Ca 2+ and increases eNOS activity (Cao et al., 2001)